ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to Charles River
DUBLIN, Ireland, December 6, 2017 - ERS Genomics today announced a patent license agreement whereby U.S.-based Charles River Laboratories International, Inc. gains non-exclusive access to the Company’s CRISPR/Cas9 patents to offer customers an expanded range of in vivo and in vitro genome editing services. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology. Financial details of the agreement were not disclosed.
“Charles River has a reputation for excellent science and we are pleased to include them as one of the leading worldwide contract research organizations into our portfolio of licensees,” said Eric Rhodes, CEO of ERS Genomics. “Overall, 2017 has been a very successful year for ERS in making the CRISPR/Cas9 patents widely accessible to biotechnology and pharmaceutical companies. Today’s announcement represents a total of twelve licensing agreements this year with companies of all sizes.”
Biologists at Charles River employ CRISPR/Cas9 for target screening alone or alongside the Company’s proprietary RNAi screening platform and library to create complex, custom knock-in and knockout cell lines with applications throughout the drug discovery continuum.
ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.